natgillin/translations-raw huggingface dataset:
The method according to claim 5, wherein the L1 signaling information has data slice ID information that identifies the data slice. 
Metoda u skladu s patentnim zahtjevom 5, pri čemu L1 informacija signaliziranja ima ID informaciju podatkovnog Teza koja identificira podatkovni rez.
L-methionine at a concentration of about 250 mg/L; and a combination of ascorbic acid at a concetration of about 30 mg/L and of (+)-alpha-tocopherol at a concentration of about 14 mg/L. 
L-metionin u koncentraciji od oko 250 mg/L; i kombinaciju askorbinske kiseline u koncentraciji od oko 30 mg/L, te (+)-alfa-tokoferol u koncentraciji od oko 14 mg/L.
Ingested surfactants may facilitate penetration or absorption of potentially toxic or pathogenic compounds, which in turn may result in adverse effects on the other organs (Lieberman, H. A., Rieger, M. M. and Banker, G. S., Eds., Pharmaceutical Dosage Forms: Disperse Systems, 2nd ed, Vol. 
Progutani surfaktanti mogu olakšati unos ili apsorpciju potencijalno toksičnih ili patpgenih spojeva, koji naizmjence mogu rezultirati u suprotnom učinku na ostale organe (Lieberman, H.A., Rieger, M.M. i Banker, G.S., Ur., Pharmaceutical Dosage Forms: Disperse Systems, 2. izd, Vol.
server-side monitoring the quality of the transmitted audio signal. 
D) praćenja kvalitete prenesenog audio signala sa strane poslužitelja.
The annular support skirt 18 now covers the end of the flange-like rim 6 of the capsule 1 to ensure that the sealing member 8 and the capsule as such remain in position when the sealing surface 15 of the bell member exerts a certain pressure force of the sealing member 8. Actually, the lip-shaped sealing member 8 represents an example of a construction for providing a self-reinforcing sealing engagement. 
Kružni potporni rub 18 sada prekriva krajnji dio ruba 6 čahure 1, koji rub čahure ima oblik prirubnice, da bi se na taj način osiguralo da element za nepropusno zatvaranje 8 i čahura, kao takvi, ostanu u položaju kada se površina za brtvljenje 15 zvonastog elementa podvrgne stanovitoj sili tlaka elementa za nepropusno zatvaranje 8.
Use according to claim 5, wherein said biocontrol is in agriculture. 
Sastav za upotrebu prema kojem od prethodnih zahtjeva, gdje:
is selected from the group consisting of hydrogen, C1-4 alkyl; 
R7 se bira iz skupine koju čine vodik i C1-4 alkil;
The composition according to [27], wherein the CB1 cannabinoid receptor synthetic agonist is selected from the group consisting of HU-210 and arachidonyl-2'-chloroethylamide (ACEA). 
Pripravak u skladu s patentnim zahtjevom 8, naznačen time što se agonist kanabinoidnog receptora CB, bira iz skupine koju čine HU-210 i arahidonil-2'-kloretilamid (ACEA).
Magnetic core comprising a stack of electrical steel sheets with a known preferential direction of permeability, wherein in the stack the preferential direction of permeability of successive single sheets and / or groups of sheets differs by a predetermined shift angle, wherein the stack of electrical steel sheets of the magnetic core is made of grain oriented electrical steel sheets, characterized in that the shift angle is between 50° and 70°. 
PATENTNI ZAHTJEVI Magnetska jezgra, koja se sastoji od sloga od limova od električnog čelika s poznatim preferencijalnim smjerom permeabilnosti, gdje se u slogu preferencijalni smjer permeabilnosti za uzastopne pojedinačne limove i/ili skupine limova razlikuje po predodređenom kutu pomaka, gdje je slog od limova električnog čelika u magnetskoj jezgri načinjen od limova od električnog čelika orijentiranih po zrnu, naznačena time što je kut pomaka između 50% 1 70".
The assembly according to claim 1, wherein said hollow voice prosthesis tubing (20) includes an opening (22) in a side thereof for receiving said voice prosthesis therethrough, and includes a lubricant with a coefficient of friction of 0.04 ≤ µk ≤ 1 between the voice prosthesis (30) and the voice prosthesis holder (20). 
Sklop u skladu s patentnim zahtjevom 1, naznačen time što navedena šuplja cijev za govornu protezu (20) uključuje otvor (22 u njezinoj strani za prihvaćanje kroz nju navedene govorne proteze, te uključuje sredstvo za podmazivanje s koeficijentom trenja od 0.04 < uy < I između govorne proteze (30) 1 držača govorne proteze (20).
The compound or enantiomer, diastereomer, tautomer, or pharmaceutically-acceptable salt or solvate thereof for use according to claim 10, wherein in case of (2), the compound is for treating a disorder associated with aberrant Stat3 pathway activity in a subject, wherein aberrant Stat3 pathway activity can be identified by the expression of phosphorylated Stat3 or a surrogate upstream or downstream regulator of Stat3 phosphorylation, and wherein the disorder is a cancer selected from the group consisting of breast cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, multiple myeloma, colorectal carcinoma, prostate cancer, renal cell carcinoma, melanoma, hepatocellular carcinoma, cervical cancer, sarcomas, brain tumors, gastric cancers, multiple myeloma, leukemia and lymphomas; 
Spoj prema zahtjevu 12 gdje je u slučaju (1) spoj za liječenje poremećaja povezanog s neprirodnom aktivnošću signalnog puta Stat3 u subjekta i gdje se neprirodna aktivnost signalnog puta Stat3 može odrediti ekspresijom fosforiliranog Stat3 ili surogatom uzvodnog ili nizvodnog regulatora Stat3 fosforilacije i gdje je poremećaj (i) rak izabran iz skupine koju čine rak dojke, rak glave i vrata, rak pluća, rak jajnika, rak gušterače, kolorektalni karcinom, rak prostate, karcinom renalnih stanica, melanom, hepatocelularni karcinomi, rak cerviksa, sarkomi, tumori mozga, rakovi želuca, multipli mijelom, leukemija, limfomi;
A starter culture obtained by the method of Claim 1. 
Starter kultura naznačena time da se dobiva pomoću postupka prema zahtjevu 1.
The inboard wall 340 has a radially inner surface 342, and a radially outer surface 344 radially inward of the inner surface 242 of the first valve retainer 234 . 
234, 434, 534), koje se u najmanju ruku dijelom nalazi u unutarnjem prolazu grla spremnika i ima radijalnu unutarnju površinu (42.
The liquid composition may be filled in capsules made of an absorbable material such as gelatin. 
Tekući pripravak može se puniti u kapsule načinjene od apsorbabilnog materijala, poput želatine.
Device according to claim 1, wherein one or more mowing units are arranged in front of the caterpillar chassis. Device according to claim 1, wherein the sweeping roller has its own drive unit. 
Uređaj sukladno bilo kojem od zahtjeva 1 do 4, naznačen time što roler (6) ima vlastitu pogonsku jedinicu.
a compound of formula I 
(A) spoja formule (I) ta
The nutrition according any of the preceding claims wherein the non-digestible oligosaccharide is selected from the group consisting of fructo-oligosaccharide, non-digestible dextrin, galacto-oligosaccharide, xylo-oligosaccharide, arabino-oligosaccharide, arabinogalacto-oligosaccharide, gluco-oligosaccharide, glucomanno-oligosaccharide, galactomanno-oligosaccharide, mannan-oligosaccharide, chito-oligosaccharide, uronic acid oligosaccharide, sialyloligosaccharide and fuco-oligosaccharide 
Hrana u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je neprobavljivi oligosaharid odabran iz skupine koju čine frukto-oligosaharid, ne-probavljivi dekstrin, galakto-oligosaharid, ksilo-oligosaharid, arabino-oligosaharid, arabinogalakto-oligosaharid, gluko-oligosaharid, glukomano-oligosaharid, galaktomanooligosaharid, manan-oligosaharid, chito-oligosaharid, oligosaharid uronske kiseline, sialiloligosaharid i fukooligosaharid.
Active ingredient C 
Aktivni sastojak C
The application of the compositions according to the invention can be for instance once a day, or depending on the duration of action of the anticholinergic agent twice a day, or once every 2 or 3 days. 
Kombinacije sukladno predmetnom izumu mogu se davati jedanput na dan ili, ovisno o trajanju djelovanja antikolinergijskog sredstva, dvaput na dan ili jedanput svaka 2 ili 3 dana, pa čak i "prema potrebi" (u odredenim danima, tri ili više puta na dan).
condensing the expanded DPFs into cell aggregates that exhibit the size and shape of the physiological DP, wherein said DPFs are differentiated in non-adhesive culture vessels in a cell concentration per vessel surface of 1.000 to 100.000 DPFs/cm2. 
(d) kondenziranja ekspandiranih DPF-ova u stanične agregate koji iskazuju veličinu 1 oblik fiziološke DP, pri čemu su navedeni DPF-ovi diferencirani u ne-adhezivnim posudama sa kulturom u staničnoj koncentraciji na površini posude od 1.000 do 100.000 DPF/cm', te
The light dose was 2700 KJ/m2 during 60 minutes. 
Doza svjetla je bila 2700 KJI/m' tijekom 60 minuta.
melphalan flufenamide, or a pharmaceutically acceptable salt thereof, is dissolved in an organic solvent; 
melfalan flufenamid hidroklorid (J1) se otopi u organskom otapalu;
The cells for the use according to claim 1, wherein said ischemia is selected from the group consisting of peripheral arterial disease (PAD) and ischemia of the central nervous system (CNS). 
Stanice ili proizvodni artikl, namijenjeni upotrebi u skladu s patentnim zahtjevima 1 ili 2, naznačeni time što se navedena ishemija bira iz skupine koju čine bolest perifernih arterija (PAD) 1 ishemija središnjeg živčanog sustava (CNS).
A heterocyclyl may be saturated, unsaturated, aromatic (e.g., heteroaryl), nonaromatic, or fused. 
Heterociklička struktura može biti zasićena, nezasićena, aromatska (npr. heteroaril), nearomatska ili spojena.
Position information providing system indoor transmitter and method for providing position information 
SUSTAV ZA PRUŽANJE INFORMACIJA O POLOŽAJU, UNUTARNJI ODAŠILJAČ | POSTUPAK PRUŽANJA INFORMACIJA O POLOZAJU
A composition comprising at least one isolated IL-23p19 antibody according to any of claims 1-8 and at least one pharmaceutically acceptable carrier or diluent, optionally further comprising at least one compound or polypeptide selected from a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, and a cytokine antagonist. 
Pripravak koji sadrži najmanje jedno izolirano IL-23p19 protutijelo prema bilo kojem od zahtjeva 1-5 i najmanje jedan farmaceutski prihvatljiv nosač ili otapalo, koji po potrebi nadalje sadrži jedan spoj ili polipeptid koji je odabran od detektabilnog obilježivača ili reportera, TNF antagonista, protuupalnog lijeka, kardiovaskularnog sistemskog lijeka (CV), lijeka za središnji živčani sustav (CNS), lijeka za autonomni živčani sustav (ANS), lijeka za dišne putove, lijeka za gastrointestinalni trakt (GI), hormonskog lijeka, lijeka za uspostavljanje ravnoteže tekućina ili elektrolita, hematološkog lijeka, antineoplastika, imunomodulacijskog lijeka, lijeka za oči, uši ili nazalnog lijeka, topikalnog lijeka, nutritivnog lijeka, citokina, i antagonista citokina.
The compound of claim 4 where Y is phenyl, optionally substituted with 1 or 2 fluoro, chloro, methyl, hydroxy, methoxy, or trifluoromethyl groups. 
Spoj iz zahtjeva 4, naznačen time, da Y je fenil, po izboru supstituiran sa 1 ili 2 fluoro, kloro, metil, hidroksi, metoksi ili triflormetilnom skupinom.
The pyridine derivative or the pharmaceutically acceptable salt thereof, according to claim 2, wherein R2 is a hydrogen atom, a methyl group, an ethyl group, a cyclopropyl group, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, an isobutyloxy group, a benzyloxy group, a methylthio group, a fluorine atom, a chlorine atom, a bromine atom, a cyano group, a hydroxyl group, a trifluoromethyl group, a difluoromethyl group, a nitro group, a phenyl group, or a phenoxy group. 
Derivat piridina ili njegova farmaceutski prihvatljiva sol, ili njegov solvat prema zahtjevu 6, naznačen time da R2 je vodikov atom, metilna skupina, etilna skupina, ciklopropilna skupina, metoksi skupina, etoksi skupina, propoksi skupina, izopropoksi skupina, izobutiloksi skupina, benziloksi skupina, metiltio skupina, fluorov atom, klorov atom, bromov atom, cijano skupina, hidroksilna skupina, pirolidin-1-il skupina, trifluorometilna skupina, difluorometilna skupina, nitro skupina, fenilna skupina, ili fenoksi skupina.
Many of the current treatment regimes for diseases resulting from the abnormal regulation of cellular proliferation such as psoriasis and cancer, utilise compounds that inhibit DNA synthesis and cellular proliferation. 
U velikom broju postojećih režima liječenja bolesti prouzročenih abnormalnom regulacijom proliferacije stanica, poput psorijaze i raka, koriste se spojevi koji inhibiraju sintezu DNA i proliferaciju stanica.
Images were imported into Photoshop (Adobe) with a AGFA slide scanner. 
Slike su unesene u program Photoshop (Adobe) s AGFA kliznim pretraživačem.
a plug insertion channel, the plug insertion channel extending around the socket connection portion; 
- kanal (4) za umetanje utikača, gdje se kanal za umetanje utikača proteže oko spojnog dijela (2) utičnice;
The process of claim 16, wherein the operating pressure of the flash vessels is increased to reduce vaporization of a contaminant. 
. Proces prema patentnom zahtjevu 3, naznačen time, da se radni pritisak posuda za isparavanje povećava da bi se smanjilo isparavanje kontaminanta, t>&
reacting the compound of formula IX or an acid addition salt thereof wherein R1 is -(CO)NH2, -CH2NH2 or -CN with i) a five or six membered heterocyclic aromatic compound comprising at least one N-atom being a part of an imine-group, or ii) tetrazole to form a compound of formula VII wherein R1 and X are as defined above; 
reakciju spoja sa formulom IX ili njegove kisele adicijske soli [image] pri čemu R1 je -(CO)NH2, -CH2NH2 ili -CN sa pet ili šest članim heterocikličkim aromatskim spojem koji sadrži barem jedan N-atom koji je dio iminske-skupine, ili ii) tetrazolom da se dobije spoj sa formulom VII [image] pri čemu R1 i X su kako je gore definirano;
The method according to claim 1, further comprising: continuously analyzing a statistical type of waveforms relating to passages of the pig device through the welding seams between the pipe sections forming the pipeline and possible variations and/or anomalies of the internal section of said pipeline, and different sound attenuation due to various propagation distances, wherein a sound propagation model, which includes calculation of the sound speed and attenuation in the fluid, is continuously acquired and experimentally updated. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što uključuje korak kontinuirane analize statističkog tipa valnih oblika povezanih s prolaženjem prasice (10) kroz varne šavove između cijevnih odjeljaka koji tvore cjevovod (12) i mogućih varijacija i/ili anomalija unutarnjeg odjeljka navedenog cjevovoda (12), uzevši također u obzir različito prigušenje zvuka zbog različitih daljina širenja, gdje se model širenja zvuka, koji uključuje izračunavanje brzine i prigušenja zvuka u fluidu, kontinuirano stvara i dopunjuje eksperimentalno.
The composition of claim 4 wherein the amino-terminal leader extension comprises or consists of VHS-. 
Sastav prema zahtjevu 4, naznačen time, da aminozavršno produljenje predvodničke sekvence obuhvaća ili se sastoji od VHS-.
Crystalline rilapladib as claimed in claim 2 or claim 3, wherein the X-ray powder diffraction pattern further comprises diffraction angles (2 theta) at least at positions of 11.7, 12.4, 13.1, 14.0,14.9, 15.3, 16.5, 16.8, 17.5, 17.8, 18.5, 18.9, 19.3, 20.0, 20.6, 21.1, and 22.1, each ± 0.1 degrees. 
Kristalni rilapladib u skladu s patentnim zahtjevom 2 ili patentnim zahtjevom 3, naznačen time što uzorak difrakcije rendgenskih zraka na prahu dodatno sadrži difrakcijske kuteve (2θ) u najmanju ruku na položajima od 11,7, 12,4, 13,1, 14,0, 14,9, 15,3, 16,5, 16,8, 17,5, 17,8, 18,5, 18,9, 19,3, 20,0, 20,6, 21,1, te 22,1, svaki ± 0,1°.
At least one of the ovens may include an ejector moveable between a retracted configuration and an expanded configuration, wherein movement of the ejector from the retracted configuration to the expanded configuration moves the contents of the oven out of the oven without the contents being touched by a human, and the at least one controller causes the ejector to move the contents of the oven out of the oven without the contents being touched by a human in response to reaching a defined cooking time for a set of temperatures at which the respective oven was operated during at least part of a transit of the vehicle based on a dynamically updated estimated transit time to a delivery destination of the contents of the respective oven. 
Postupak prema zahtjevu 9, naznačen time, da najmanje jedan od štednjaka (210) obuhvaća uređaj za izbacivanje (246) koji je pomičan između uvučene konfiguracije 1 rastegnute konfiguracije, te time, da nadalje obuhvaća sljedeće: pozicioniranje uređaja za izbacivanje na temelju dimenzija sadržina iz štednjaka, u svrhu uravnoteženja sadržaja u štednjaku, za sprečavanje njegovog pomicanja za vrijeme putovanja vozila (240).
The compound according to any one of claims 13 to 19, or the pharmaceutically acceptable salt thereof or the solvate thereof, wherein R3a is hydrogen, lower alkyl optionally substituted by substituent group C, carbocyclic group optionally substituted by substituent group C, heterocyclic group optionally substituted by substituent group C, carbocycle lower alkyl optionally substituted by substituent group C, (substituent group C is same as that of claim 13). 
Spoj prema bilo kojem od zahtjeva 13 do 18, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat, naznačen time, da R* je vodik, niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, heterociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbociklički niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, (Supstituentska skupina C ima isto značenje kao što je navedeno u zahtjevu 13).
Oxycodone HCl, lactose, and povidone are placed into a fluid bed granulator/dryer (FBD) bowl, and the suspension sprayed onto the powder in the fluid bed. 
Oksikodon HCI, laktoza i povidon postavljeni su u fluidiziranom sloju u posudu granulatora/sušilice (EBD), te je suspenzija raspršena u prah u fluidiziranom sloju.
Y=—N(CH3)3+ quaternary ammonium group; the other substituents being as defined above. 
Y = -N(CH;);* kvaterna amonijeva skupina, ostali supstituenti su gore definirani.
The use according to claim 7, wherein the neuropathic condition is painful diabetic neuropathy (PDN) or a related condition. 
Uporaba prema zahtjevu 9, naznačena time da periferna neuropatska bol potječe od bolne dijabetičke neuropatije (PDN) ili povezanog stanja.
Ry and Rz, together with the nitrogen atom to which they are attached, form a heterocyclyl or heteroaryl, optionally substituted with one or more, in one embodiment, one, two or three Q7 groups; each Q7 is independently selected from halo, deuterium, oxo, thioxo, hydroxy, alkoxy, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl; 
(Hi) Ri R", zajedno s atomom dušika za koji su pričvršćeni, tvore heterociklil ili heteroaril, opcionalno supstituiran s jednom, dvije ili tri Q' grupa; svaka Q' grupa je nezavisno odabrana između halo, deuterija,okso, tiokso, hidroksila, alkoksila, alkila, haloalkila, hidroksialkila, aminoalkila, alkenila, alkinila, -cikloalkila, cikloalkenila, cikloalkilalkila, cikloalkenilalikla, arila, aralkila, heteroarila, heteroaralkila, heterociklila i heterociklilalkila;
Theta range for data collection 
P2, Theta raspon
After concentration in vacuo, the residue was diluted with EtOAc (150 mL), washed with H2O and brine, dried (Na2SO4), and concentrated to afford 141 mg (20%) of Compound 9.4A as an isomer mixture. 
Nakon koncentriranja in vacuo, ostatak se razrijedi s EtOAc (150 mL), ispere sa H2O i otopinom soli, suši (Na,SOy), te koncentrira da bi se dobilo 141 mg (20%) Spoja 9.4A kao smjese izomera.
Use of the extracts from rabbit skin inflamed by vaccinia virus in the manufacture of a medicament for treatment of acute cerebrovascular diseases in a mammal. The use of claim 1, wherein said acute cerebrovascular diseases are acute ischemic cerebrovascular diseases. The use of claim 2, wherein said acute ischemic cerebrovascular diseases are selected from the group consisting of cerebral embolism, transient cerebral ischemia attack, cerebral thrombosis, cerebral arteriosclerosis, cerebral arteritis, steal syndrome of cerebral artery, cranial venous sinus and venous thrombus. 
Analgecine za uporabu kao lijek za liječenje akutne ishemijske cerebrovaskularne bolesti, gdje se nakon ishemije moždanog tkiva analgecine koristi za zaštitu živčanih stanica od ozljede ili za smanjenje razine mliječne kiseline u moždanom tkivu ili za povećanje aktivnosti superoksid dismutaze, i gdje se akutna ishemijska cerebrovaskularna bolest odabire iz skupine koju čine cerebralna embolija, tranzitna cerebralna ishemijska ataka, cerebralna tromboza, cerebralna arterioskleroza, cerebralni arteritis, sindrom krađe cerebralne arterije, kranijalni venski sinus i venski tromb.
The pharmaceutical composition for use according to claim 2, wherein Rb3 and Rb5 are independently selected from hydrogen, methyl, C1-C6 alkyl substituted with heterocyclyl, and unsubstituted C1-C6 alkoxy wherein Rb2 and Rb3 and/or Rb5 and Rb6 may be connected to form a phenyl ring. 
Farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da su Rb; i Rbs neovisno odabrani od sljedećih: vodik, metil, C,-Cg alkil supstituiran s heterociklom, i nesupstituirani C,-Cg alkoksi, gdje Rb2i Rbs i/ili Rbs i Rb; mogu biti spojeni za tvorbu fenilnog prstena.
Method for preventing, slowing, delaying or treating the degeneration of pancreatic beta cells and/or the decline of the functionality of pancreatic beta cells and/or for improving and/or restoring the functionality of pancreatic beta cells and/or restoring the functionality of pancreatic insulin secretion in a patient in need thereof characterized in that an SGLT2 inhibitor, a DPP IV inhibitor and a third antidiabetic agent according to claim 1 are administered to the patient. 
prevencija, usporavanje, odgađanje ili liječenje degeneracije beta stanica gušterače i/ili propadanja funkcionalnosti beta stanica gušterače i/ili poboljšanje i /ili obnavljanje funkcionalnosti beta stanica gušterače i/ili obnavljanje funkcionalnosti sekrecije inzulina u gušterači; ili
providing on the first waterproofing layer (15) an internally hollow structure (16) whose inner face (17), directed toward the inside of the basin, is substantially vertical, adapted to provide a substantially vertical wall of the central tank (V), 
- osiguravanje na prvom vodootpornom sloju (15) unutarnje šuplje strukture (16) čija je unutarnja strana (17), usmjerena prema unuttrašnjosti osnove, supstancijalno vertikalna, prilagođena da osigurava supstancijalno vertikalni zid središnjeg spremnika (V),
The pharmaceutical composition according to claim 1, wherein the suspending particles remain co-located with the active agent particles even when subjected to buoyancy forces amplified by centrifugation at an acceleration selected from accelerations of at least 1 g, at least 10 g, at least 50 g, and at least 100 g. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što suspendirajuće čestice ostaju ko-locirane s česticama aktivnog sredstva čak i kada ih se podvrgava uzgonskim silama uvećanim centrifugiranjem uz ubrzanje koje se bira između ubrzanja od najmanje 1 g, najmanje 10 g, najmanje 50 g, te najmanje 100 g.